Select Page

Sapphire Biotech, a facet of Axim, has partnered with ASU by providing licensing technology to support research that strives to inhibit one of the enzymes that facilitates the spread of cancer in the body.

Sapphire Biotech will work with ASU by conducting preclinical studies using QSOX1 inhibitors. The studies will be done with SBI-183, one of Sapphire’s licensed technologies.

This sponsorship research agreement was facilitated by Skysong Innovations, a group that works “with ASU and other partner institutions to translate research into real-world impact.”

This research is based on the efforts of Douglas Lake, an associate professor and tumor immunologist at the School of Life Sciences at ASU, as well as co-founder of Sapphire Biotech, an acquiree of Axim.